Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.29.15_SUPPL.8542PMID 28021081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

  2013cites this paper
• Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

  2013cites this paper
• Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities

  2012cites this paper
• Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

  2012cites this paper
• The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence

  2012cites this paper
• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  2011cites this paper